NRIX
Nurix Therapeutics Inc

638
Mkt Cap
$1.48B
Volume
5.44M
52W High
$22.50
52W Low
$8.18
PE Ratio
-4.74
NRIX Fundamentals
Price
$14.43
Prev Close
$14.92
Open
$14.92
50D MA
$16.70
Beta
1.63
Avg. Volume
868,011.76
EPS (Annual)
-$3.05
P/B
2.73
Rev/Employee
$264,921.14
$995.06
Loading...
Loading...
News
all
press releases
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -374.36% and -89.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX
Cinctive Capital Management LP raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 64.5% during the 3rd quarter, according to its most recent disclosure with the Securities...
MarketBeat·5d ago
News Placeholder
Nurix Therapeutics, Inc. $NRIX Stake Cut by Commodore Capital LP
Commodore Capital LP trimmed its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4.3% during the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·7d ago
News Placeholder
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX
ARK Investment Management LLC cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4.1% in the third quarter, according to the company in its most recent disclosure...
MarketBeat·17d ago
News Placeholder
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX
Handelsbanken Fonder AB grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 85.7% during the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·19d ago
News Placeholder
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Key PointsRedmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade value was $63.43 million based on quarterly average pricing...
Nasdaq News: Markets·28d ago
News Placeholder
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the stock, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight
Executives from Nurix Therapeutics (NASDAQ:NRIX) used a recent discussion on the company's immunology and inflammation (I&I) efforts to outline why the firm believes targeted protein degradation...
MarketBeat·1mo ago
News Placeholder
Research Analysts Offer Predictions for NRIX Q1 Earnings
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Nurix Therapeutics in a report released on Thursday...
MarketBeat·2mo ago
News Placeholder
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 3,661 Shares of Stock
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 3,661 shares of the business's stock in a transaction dated Friday, January 30th. The shares were sold at an average...
MarketBeat·2mo ago
<
1
2
...
>

Latest NRIX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.